Key terms
About LGND
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LGND news
Apr 12
7:23am ET
Analysts Are Bullish on Top Healthcare Stocks: Select Medical (SEM), Ligand Pharma (LGND)
Apr 08
8:21am ET
Ligand announces new topiramate injection data
Apr 03
9:14am ET
Ligand announces launch of Pelthos, appointment of Plesha as its CEO
Mar 08
8:45am ET
Ligand Pharma (LGND) Gets a Buy from Craig-Hallum
Mar 06
4:55am ET
Ligand management to meet with Craig-Hallum
Mar 02
1:06am ET
Ligand Pharmaceuticals Inc’s New Competition Risk – A Cause for Worry?
Mar 01
11:04am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
6:30am ET
Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), Springworks Therapeutics (SWTX)
Feb 28
7:32am ET
Analysts Offer Insights on Healthcare Companies: Fulcrum Therapeutics (FULC), Ligand Pharma (LGND) and Alphatec Holdings (ATEC)
Feb 28
3:40am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ligand Pharma (LGND), Agilent (A) and Eli Lilly & Co (LLY)
Feb 27
1:07pm ET
Ligand management to meet with Craig-Hallum
Feb 27
7:13am ET
Ligand sees FY24 EPS $4.25 -$4.75, consensus $4.27
Feb 27
7:11am ET
Ligand reports Q4 EPS $1.38, consensus 66c
Feb 26
3:45am ET
Ligand Pharma (LGND) Receives a Buy from Barclays
Feb 23
9:03am ET
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Celcuity (CELC)
Feb 22
4:13pm ET
Ligand partner Eisai receives Japan approval for Fycompa injection
Jan 29
5:06am ET
Barclays Remains a Buy on Ligand Pharma (LGND)
No recent press releases are available for LGND
LGND Financials
Key terms
Ad Feedback
LGND Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LGND Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
